Next year, that's right. To you that means Jan 1st (or any other idiot that doesn't read the whole update). If YOU READ the rest, you'll see clinical in Q32021 with data in 2022.
"The Company plans to initiate its first in-human clinical study for the treatment of glaucoma in Q32021 with data anticipated in early 2022. The study will consist of a single ascending dose (SAD) arm in healthy volunteers, followed by a multiple ascending dose (MAD) arm in healthy volunteers, and will also assess subjects with glaucoma and/or elevated IOP."
News 
Market Data 
Discover 
